Business Description
JCR Pharmaceuticals Co Ltd
ISIN : JP3701000006
Share Class Description:
JCRRF: Ordinary SharesDescription
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.45 | |||||
| Debt-to-EBITDA | 3.09 | |||||
| Interest Coverage | 119.54 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 2.44 | |||||
| Beneish M-Score | -0.93 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.1 | |||||
| 3-Year EBITDA Growth Rate | -11 | |||||
| 3-Year EPS without NRI Growth Rate | -7 | |||||
| 3-Year FCF Growth Rate | 48.5 | |||||
| 3-Year Book Growth Rate | 9.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | -1.9 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -42.26 | |||||
| 12-1 Month Momentum % | -51.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Days Inventory | 814.44 | |||||
| Days Sales Outstanding | 121.99 | |||||
| Days Payable | 60.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.59 | |||||
| Dividend Payout Ratio | 0.45 | |||||
| 3-Year Dividend Growth Rate | -3.9 | |||||
| Forward Dividend Yield % | 2.47 | |||||
| 5-Year Yield-on-Cost % | 7.59 | |||||
| 3-Year Average Share Buyback Ratio | -0.3 | |||||
| Shareholder Yield % | -3.32 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 80.35 | |||||
| Operating Margin % | 17.57 | |||||
| Net Margin % | 12.85 | |||||
| FCF Margin % | 21.12 | |||||
| ROE % | 10.24 | |||||
| ROA % | 5.59 | |||||
| ROIC % | 6.32 | |||||
| ROC (Joel Greenblatt) % | 15.81 | |||||
| ROCE % | 10.36 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 14.17 | |||||
| PE Ratio without NRI | 14.13 | |||||
| Shiller PE Ratio | 16.15 | |||||
| PEG Ratio | 1.7 | |||||
| PS Ratio | 1.82 | |||||
| PB Ratio | 1.51 | |||||
| Price-to-Tangible-Book | 1.51 | |||||
| Price-to-Free-Cash-Flow | 8.38 | |||||
| Price-to-Operating-Cash-Flow | 8.38 | |||||
| EV-to-EBIT | 10.97 | |||||
| EV-to-Forward-EBIT | 18.07 | |||||
| EV-to-EBITDA | 10.97 | |||||
| EV-to-Forward-EBITDA | 14.63 | |||||
| EV-to-Revenue | 1.93 | |||||
| EV-to-Forward-Revenue | 3.82 | |||||
| EV-to-FCF | 8.87 | |||||
| Price-to-Projected-FCF | 1.78 | |||||
| Price-to-DCF (Earnings Based) | 0.37 | |||||
| Price-to-DCF (FCF Based) | 0.22 | |||||
| Price-to-Median-PS-Value | 0.34 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.62 | |||||
| Price-to-Graham-Number | 0.97 | |||||
| Earnings Yield (Greenblatt) % | 9.12 | |||||
| FCF Yield % | 12 | |||||
| Forward Rate of Return (Yacktman) % | 8.1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:JCRRF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
JCR Pharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 294.226 | ||
| EPS (TTM) ($) | 0.3 | ||
| Beta | 0.46 | ||
| Volatility % | 44.62 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0.036896 | ||
| 20-Day SMA ($) | 5.22 | ||
| 12-1 Month Momentum % | -51.46 | ||
| 52-Week Range ($) | 5.22 - 10.755 | ||
| Shares Outstanding (Mil) | 124.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
JCR Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
JCR Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
JCR Pharmaceuticals Co Ltd Frequently Asked Questions
What is JCR Pharmaceuticals Co Ltd(JCRRF)'s stock price today?
The current price of JCRRF is $5.22. The 52 week high of JCRRF is $10.76 and 52 week low is $5.22.
When is next earnings date of JCR Pharmaceuticals Co Ltd(JCRRF)?
The next earnings date of JCR Pharmaceuticals Co Ltd(JCRRF) is .
Does JCR Pharmaceuticals Co Ltd(JCRRF) pay dividends? If so, how much?
The Dividend Yield %  of JCR Pharmaceuticals Co Ltd(JCRRF) is 2.59% (As of Today), Highest Dividend Payout Ratio of JCR Pharmaceuticals Co Ltd(JCRRF) was 0.66. The lowest was 0.16. And the median was 0.38. The  Forward Dividend Yield % of JCR Pharmaceuticals Co Ltd(JCRRF) is 2.47%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers